BY Christopher Karlsson
-
French biotech Sensorion raises EUR 60m for gene therapy targeting hearing loss
Amongst the capitalists is the French pharmaceutical firm Sanofi.
-
Catalent to close Belgian facility with focus on cell therapies
Nevertheless, the closure of the Belgian center has absolutely nothing to do with Novo Nordisk’s current choice to cease r & d in cell treatments, according to proprieto…
-
Novo Nordisk launches new Ozempic campaign featuring US actors
The brand-new project has actually been called “There’s just one Ozempic,” and the objective is to notify individuals regarding exactly how this diabetes mellitus…
-
Novo Nordisk divests cell technology rights in new collaboration
Along with getting the legal rights, Canadian firm Facet Biosystems will certainly lead the advancement, production, and advertising and marketing of any type of prospects occurrin…
-
Funds support 18 projects in the fight against antibiotic resistance
The 3 structures, consisting of the Novo Nordisk Structure, are likewise raising their payments to the chosen study tasks.
-
Novo Nordisk launches new Ozempic campaign featuring US actors
The new campaign has been named ”There’s only one Ozempic,” and the aim is to inform people about how this diabetes medication differs from other medications.
-
Funds support 18 projects in the fight against antibiotic resistance
The three foundations, including the Novo Nordisk Foundation, are also increasing their contributions to the selected research projects.
-
Novo Nordisk launches crucial trial with weight loss hope
According to an expert at AL Sydbank, Amycretin, which will certainly currently be checked in stage III tests, is among one of the most vital prospects in Novo Nordisk’s late…
-
German Exciva raises EUR 51m for Phase 2 Alzheimer’s study
The cash from the brand-new round of funding will mostly be made use of for a Stage 2 research study on anxiety in people with Alzheimer’s condition.
-
Valneva halts applications for chikungunya vaccine in US
With Valneva’s withdrawal, Bavarian Nordic is the only continuing to be business that has actually marketed an injection versus chikungunya infection in the United States.
